Medical Technology Breaking News: Aethlon Medical
(AEMDD) Announces Institutional Review Board Approval of Multi-Indication
Cancer Study
SAN DIEGO - May 12, 2015 (Investorideas.com newswire) Aethlon
Medical, Inc. (OTCQB:AEMD, AEMDD), a pioneer in developing
targeted therapeutic devices to address infectious diseases and cancer,
announced today that the Institutional Review Board (IRB) of the University of
California, Irvine (UCI) has approved a multi-indication clinical study
entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing
Treatment."
Aethlon
previously disclosed that it had entered into investigator-initiated clinical
trial agreement with UCI, which was pending IRB approval. Under the approved
clinical protocol, the study will seek to enroll five individuals in each of
nine defined tumor types for a total study population of up to 45 subjects. The
tumor types include the following forms of cancer; Breast adenocarcinoma,
Colorectal, Gastric & Gastroesophageal, Pancreatic, Cholangiocarcinoma,
Lung (NSCLC), Head & Neck (SCC), Melanoma and Ovarian adenocarcinoma. The
principal investigator of the study is Edward Nelson, M.D.
The
study endpoints include establishing baseline exosome levels and monitoring
changes in circulating exosome concentration associated with tumor treatment
and the association of longitudinal changes in circulating exosome
concentrations with response to treatment. Recruitment of participants in the
study will be through the use of internal and outside referrals to the
University of California, Irvine Medical Center (UCIMC).
The
clinical study will also provide data to help direct future clinical investigations
of the Aethlon Hemopurifier® as a therapeutic candidate to reduce the presence
of circulating tumor-derived exosomes, which are known to suppress the immune
system of cancer patients and contribute to the spread of metastasis. The
Hemopurifier® is a first-in-class biofiltration device that targets the
single-use removal of viruses and tumor-derived exosomes from the circulatory
system.
About Aethlon Medical, Inc.
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease and cancer. The company's lead product is the Aethlon
Hemopurifier®, a first-in-class device that selectively targets the rapid
elimination of circulating viruses and tumor-secreted exosomes that promote
cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that
is advancing exosome-based products to diagnose and monitor cancer, infectious
disease and neurological disorders. Additional information can be found on-line
at http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that Exosome Sciences, Inc. will not be able to
commercialize its future products, including any that can be described as a
liquid biopsy, that the FDA will not approve the initiation of the Company's clinical
programs or provide market clearance of the company's products, future human
studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system
or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its planned
products, the Company's ability to manufacture its products either internally
or through outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the ability
of the Company to meet the milestones contemplated in the DARPA contract,
product liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including the
risks associated with the effect of changing economic conditions and other risk
factors detailed in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise.
Contacts:
David
Zazoff
MDM Worldwide Solutions
646-403-3554
MDM Worldwide Solutions
646-403-3554
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for more
info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
